DexCom, Inc. (DXCM)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1,927 | 2,449 | 2,910 | 3,622 | 4,033 | 4,662 | 4,969 | 5,230 |
| Operating profit | $m | 912 | 1,139 | ||||||
| Net profit | $m | 494 | 217 | 341 | 542 | 576 | 836 | 1,000 | 1,018 |
| EPS reported | $ | 2.09 | 2.53 | ||||||
| Operating cashflow per share | $ | 3.69 | 4.56 | ||||||
| Capex per share | $ | 0.93 | 0.90 | ||||||
| FCF per share | $ | 2.76 | 3.66 | ||||||
| Free cash flow | $m | 1,077 | 1,405 | ||||||
| Net debt | $m | -758 | -652 | ||||||
| Book value equity | $m | 2,746 | 2,621 | ||||||
| Book value per share | $ | 6.77 | 6.69 | ||||||
| Number of shares | m | 405.5 | 391.8 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 31.76 | 34.24 | ||||||
| P/B LTM | x | 9.43 | 9.88 | ||||||
| P/S LTM | x | 5.56 | 5.21 | ||||||
| P/FCF LTM | x | 24.04 | 18.43 | ||||||
| EV/EBITDA LTM | x | 19.41 | 16.91 | ||||||
| EV/Sales LTM | x | 5.66 | 6.87 | ||||||
| Earnings Yield LTM | % | +3.15% | +2.92% | ||||||
| FCF Yield | % | +4.16% | +5.43% | ||||||
| Quality | |||||||||
| ROE | % | +30.46% | +36.19% | ||||||
| ROIC | % | +16.61% | +21.60% | ||||||
| Operating margin | % | +19.56% | +22.92% | ||||||
| Gross margin | % | +60.10% | +62.47% | ||||||
| FCF/Sales | % | +23.11% | +28.27% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +47.18% | +78.17% | ||||||
| Sales Growth YoY | % | +15.60% | +23.21% | ||||||
| Net Income Growth YoY | % | +45.14% | +73.50% | ||||||
| FCF Growth | % | +70.79% | +122.77% | ||||||
| Operating Profit Growth | % | +51.97% | +89.85% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.78 | 1.00 | ||||||
| Net Debt/EBITDA | x | 0.35 | 0.19 | ||||||
| EBIT/Net interest | x | 49.83 | 75.94 | ||||||
| Net debt/market cap | % | +4.79% | +3.67% | ||||||
| Net debt/Equity | x | -0.28 | -0.25 | ||||||
| Gross debt/equity | x | 0.51 | 0.53 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free